Shire yanks Replagal US BLA, again; but is it the end of the saga?
This article was originally published in Scrip
Executive Summary
In a move that surprised analysts and patients, Shire pulled its US application for its Fabry disease product, Replagal (agalsidase alfa), among company concerns that it may have to conduct more testing.